Creative Medical Technology Holdings Inc. (CELZ) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 31.7 (OVERSOLD (<32))
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CELZ currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.93) and Max Pain ($0.71) forces dealer call-delta covering toward $4.96.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Creative Medical Technology Holdings Inc. (CELZ) dropped -5.78% to $0.68, trading at 2% of its 52-week range ($0.62 – $4.72). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today.
International Scientific Presentation Underscores Encouraging Clinical Outcomes and Additional Biological Potency Findings Supporting Cell-Free Regenerative PlatformPHOENIX, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Creative Med
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine technologies, today highlighted
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -45.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CELZ today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CELZ. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Creative Medical Technology Holdings Inc. (CELZ) ranks #981 by composite RQD confidence (27/100, grade E) and #945 by equity capitalization ($5.2M). Within this direct 5-issuer industry benchmark cohort, CELZ leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with CELZ at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CELZ
ACTIVE
Creative Medical Technology Holdings Inc. | E | 27/100 | — | 63.4% | -35.0% | -5.78% | $5.2M | Benchmark Subject |
| BTTC Black Titan Corporation | D | 48/100 | — | — | — | +4.23% | $5.3M | /bttc-vs-celz → |
| LIMN Liminatus Pharma Inc. (Class A) | D | 45/100 | — | — | -35.0% | -0.86% | $3.9M | /limn-vs-celz → |
| CRIS Curis Inc. | D- | 40/100 | — | — | -35.0% | +20.82% | $3.7M | /cris-vs-celz → |
| PMCB PharmaCyte Biotech Inc. | D- | 40/100 | — | — | -30.2% | -0.78% | $3.6M | /pmcb-vs-celz → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Creative Medical Technology Holdings Inc. (CELZ) reported GAAP revenue of $6.0K (-45.5% vs. FY2024 revenue of $11.0K , and -33.3% cumulative change since FY2023) , GAAP net income of -$6.0M, operating cash flow of -$5.9M, and free cash flow of -$5.9M (-10.5% YoY). On the balance sheet, CELZ closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $6.0K | -$6.0M | -$5.9M | -$5.9M | $7.8M | — |
| FY2024 (FY) | 2024-12-31 | $11.0K | -$5.5M | -$5.3M | -$5.3M | $6.7M | — |
| FY2023 (FY) | 2023-12-31 | $9.0K | -$5.3M | -$8.0M | -$8.0M | — | — |
As of 2026-11-01, Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $0.68 (-5.78% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CELZ ranks #981 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CELZ carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 63.4%, and ROIC of -35.0%. By comparison, BTTC (Black Titan Corporation) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $5.3M) and LIMN (Liminatus Pharma Inc. (Class A)) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $3.9M). Among the 5-stock peer group, CELZ leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
Per CELZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001187953), Creative Medical Technology Holdings Inc. generated $6.0K in revenue (-45.5% YoY), -$6.0M in net income, and -$5.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CELZ last traded at $0.68 (-5.78% on volume of 62,653 shares), positioning the stock -26.88% below its 50-day simple moving average ($0.93) and -56.96% below its 200-day simple moving average ($1.58). Across its 52-week range of $0.62 to $4.72, CELZ sits at the 1.5% percentile with a 14-day RSI of 31.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.77).
Why CELZ Stock dropped -5.78% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.